Traditional Chinese Medicine anticancer injection Kanglaite, of which China has proprietary intellectual property right, has been approved by U.S. Food and Drug Administration to enter the phase III clinical trial and will expand usage among cancer patients in the US, according to news released by Zhejiang Chinese Medical University.

Kanglaite has become the first TCM injection product that enters the phase III clinical trial in the US. It is a big progress made by China in innovative TCM studies.

Developed by Professor Li Dapeng of Zhejiang Chinese Medical University, Kanglaite injection is a unique botanically sourced molecular targeted agent prepared as a micro-emulsion for intravenous use. It is manufactured by the state of art technology with active substance extracted from a natural herbal plant "semen coicis". The medicine has applied patent for invention in 11 countries and regions, including the US, Japan, and the EU and has been on sale in many countries.

In the phase II clinical trial, major evaluation indicators have shown that the median survival time of Kanglaite treatment group is 1.9 months longer than the control group that taking regular western medicines, and the objective remission rate of the Kanglaite treatment group has been improved 85.7 percent.